Spots Global Cancer Trial Database for A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
Official Title: A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
Study ID: NCT02048488
Interventions
Study Description
Brief Summary: TSR-011 is a potent small molecule inhibitor of tyrosine kinases involved in cancer, including: 1. Anaplastic lymphoma kinase (ALK) 2. The tropomyosin-related kinases TRKA, TRKB, and TRKC This is a sequential, open-label, non-randomized study with dose escalation in Phase 1, followed by expansion at a recommended phase 2 dose.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Goodyear, Arizona, United States
, Scottsdale, Arizona, United States
, Los Angeles, California, United States
, Nashville, Tennessee, United States
, Norfolk, Virginia, United States
, Spokane, Washington, United States
, Warsaw, Mazowieckie, Poland
, Gdansk, Pomorskie, Poland
, Olsztyn, Warminsko-Mazurskie, Poland
, Poznan, Wielkopolskie, Poland
, Madrid, , Spain
, Santiago de Compostela, , Spain
, Tainan City, , Taiwan
, Taipei, , Taiwan
, London, , United Kingdom
Contact Details
Name: Dmitri Bobilev, MD
Affiliation: Tesaro, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
